Tina Marriott, President and COO of Recursion Pharmaceuticals, completed a sale of 6,000 shares of the company's Class A Common Stock on August 29, 2024. The shares were sold at a price of $7.5627 per share, resulting in a total transaction value of $45,376.20. Prior to this transaction, Marriott had exercised options to acquire the same number of shares at $1.06 each. Following the sale, Marriott's direct holdings in Recursion Pharmaceuticals amount to 521,138 shares. The transaction reflects a standard open market operation and has been fully executed.

Tina Marriott, President and COO of Recursion Pharmaceuticals, completed a sale of 6,000 shares of the company's Class A Common Stock on August 29, 2024. The shares were sold at a price of $7.5627 per share, resulting in a total transaction value of $45,376.20. Prior to this transaction, Marriott had exercised options to acquire the same number of shares at $1.06 each. Following the sale, Marriott's direct holdings in Recursion Pharmaceuticals amount to 521,138 shares. The transaction reflects a standard open market operation and has been fully executed.